Home    Back

Adipose derived mesenchymal stem cell    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
3Spinal muscular atrophy1

3. Spinal muscular atrophy    [ 179 clinical trials,   102 drugs,   (DrugBank: 26 drugs),   52 drug target genes,   78 drug target pathways]
Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 179 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02855112
(ClinicalTrials.gov)		June 201522/7/2016Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman PatientsThe Effectiveness of Allogeneic Adipose Derived Mesenchymal Stem Cells (ADMSCs) in the Phenotypic Changes of Werdnig Hoffman PatientsInfantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]Biological: Adipose derived mesenchymal stem cellTehran University of Medical SciencesNULLRecruiting5 Months12 MonthsBoth10Phase 1;Phase 2Iran, Islamic Republic of